Optimal use of intravenous landiolol in acute cardiac care

B-blockers are regarded as beneficial pharmacologic agents in cardiac care, but their role in the acute setting remains ambiguous. Increasing evidence supports the important role of landiolol in critical care, a highly cardioselective intravenous b-blocker with rapid onset of action and short elimin...

Full description

Saved in:
Bibliographic Details
Published in:Expert review of cardiovascular therapy Vol. 21; no. 11; pp. 855 - 866
Main Authors: Bezati, Sofia, Boultadakis, Antonios, Ventoulis, Ioannis, Polyzogopoulou, Eftihia, Parissis, John T.
Format: Journal Article
Language:English
Published: England 02.11.2023
Subjects:
ventricular tachycardia/fibrillation
atrial fibrillation
percutaneous coronary intervention
β1-blocker1
septic cardiomyopathy
landiolol
Acute heart failure
pharmacology
ISSN:1477-9072, 1744-8344, 1744-8344
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:B-blockers are regarded as beneficial pharmacologic agents in cardiac care, but their role in the acute setting remains ambiguous. Increasing evidence supports the important role of landiolol in critical care, a highly cardioselective intravenous b-blocker with rapid onset of action and short elimination time. Among its most valuable properties, which may aid to overcome special reservations related to b-blocker therapy in the acute setting, landiolol has a potent negative chronotropic effect while at the same time it exhibits a mild negative inotropic effect. This expert opinion review aims to present basic pharmacologic aspects of landiolol and provide current clinical research focused on its efficacy and safety. Landiolol is a valuable and safe pharmacologic agent in acute cardiac care. Japanese and European guidelines have incorporated its use for the management of atrial tachyarrhythmia in patients with cardiac dysfunction. Although emerging clinical trials have experimented its use in patients with sustained ventricular tachycardia/fibrillation, acute myocardial infarction undergoing primary percutaneous intervention and in patients with septic cardiomyopathy, more studies are needed in order to establish its value in such cardiac conditions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1477-9072
1744-8344
1744-8344
DOI:10.1080/14779072.2023.2277354